Curis, Inc. (NASDAQ:CRIS) Stock Rating Upgraded by Zacks Investment Research

Curis, Inc. (NASDAQ:CRIS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Monday, July 17th.

According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “

Several other brokerages have also recently weighed in on CRIS. ValuEngine raised Curis from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Cowen and Company reissued a “buy” rating on shares of Curis in a report on Friday, May 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Curis has an average rating of “Hold” and an average target price of $5.88.

Curis (NASDAQ:CRIS) opened at 1.72 on Monday. The firm’s market cap is $247.47 million. Curis has a 52 week low of $1.47 and a 52 week high of $3.72. The stock has a 50 day moving average of $1.93 and a 200-day moving average of $2.27.

Curis (NASDAQ:CRIS) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. The business had revenue of $2.10 million for the quarter, compared to analysts’ expectations of $2.08 million. Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. Curis’s quarterly revenue was up 23.5% on a year-over-year basis. During the same period last year, the firm posted ($0.09) earnings per share. Analysts expect that Curis will post ($0.40) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Curis, Inc. (NASDAQ:CRIS) Stock Rating Upgraded by Zacks Investment Research” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://transcriptdaily.com/2017/08/13/curis-inc-nasdaqcris-upgraded-to-hold-at-zacks-investment-research-updated-updated-updated.html.

Hedge funds have recently modified their holdings of the company. Bank of America Corp DE boosted its stake in shares of Curis by 58.7% in the first quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock worth $101,000 after buying an additional 13,448 shares during the last quarter. Prudential Financial Inc. bought a new stake in shares of Curis during the first quarter worth approximately $105,000. A.R.T. Advisors LLC bought a new stake in shares of Curis during the fourth quarter worth approximately $116,000. Dynamic Technology Lab Private Ltd boosted its stake in shares of Curis by 22.3% in the first quarter. Dynamic Technology Lab Private Ltd now owns 41,922 shares of the biotechnology company’s stock worth $117,000 after buying an additional 7,638 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new stake in Curis during the fourth quarter valued at about $183,000. Institutional investors and hedge funds own 51.67% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply